We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people – about 500,000 individuals worldwide. Symptoms include, but are not limited to: delayed developmental milestones; gross and fine motor impairment; difficulty with feeding and swallowing; issues; loss of functional speech and epilepsy.
Angelman syndrome has been reversed multiple ways in mice, clincal trials are recruiting, and the progress scientists are making is thrilling.
There are currently three clinical trials recruiting in Australia at Melbourne, Sydney and Brisbane sites.
For more information visit
Australian Clinical Trials
Parents of children with Angelman Syndrome, who know what a diagnosis like this is like, are standing by to answer your questions and assist you.
FAST has a vision of a world where lives are no longer limited by a diagnosis of Angelman syndrome.
The mission of the Foundation for Angelman Syndrome Therapeutics Australia is to improve the quality of life for individuals with Angelman syndrome through timely diagnosis, access to best practices in care and treatments, and advancing research for a cure.
Founded in the United States, Australia is just one of the Global affiliates advancing Angelman syndrome research and clinical trials. FAST also has affiliates in Canada, France, Italy, Latin America (Argentina, Chile, Colombia), Spain and the UK.
Join our annual fundraising campaig
n, Cure Angelman Now!
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
